We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Transgene Sa | LSE:0OCQ | London | Ordinary Share | FR0005175080 | TRANSGENE ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.04 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 7.9M | -22.33M | -0.2214 | -5.06 | 306.59M |
From Jun 2024 to Jul 2024
Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2024, the following resources were managed through the liquidity account:
In the first half of 2024, it was negotiated a total of:
| Purchases | 204,900 shares | € 248,651 | 894 market transactions |
| Sales | 169,972 shares | € 217,858 | 769 market transactions |
It is recalled that:
Contacts
| Transgene: Lucie Larguier Chief Financial Officer +33 (0)3 88 27 91 00 investorrelations@transgene.fr |
Attachment
1 Year Transgene Chart |
1 Month Transgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
